Hims & Hers shares rise 5%
Hims & Hers shares rose 5% amid reports of possible sales of certain unapproved peptide products.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Hims & Hers expands into Germany, shares rise 5%
The telehealth company is entering Germany, initially focusing on men's health and weight management. Its shares rose 5% on Tuesday.
Hims & Hers Shares Rise Nearly 6% as Peptide Plan Reaches White House Review
Hims & Hers Health shares rose nearly 6% Thursday, ending a three-day losing streak. A Trump administration plan to ease restrictions on peptide compounding reached White House review; the stock was down 5% for the week.
US To Strike Iran Hard
US to strike Iran as war escalates
Hims & Hers Stock Surges as Analysts Lift Price Targets
Hims & Hers Health Inc (NYSE: HIMS ) shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their respective price targets on the stock. Hims & Hers Health stock is charging ahead with explosive momentum. Why are HIMS shares rallying? What The Analysts Are Saying Canaccord Genuity analyst Mar
Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst
The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc ‘s (NYSE: HIMS ) peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained a Neutral rating while raising the price target to $36 from $25. The FDA released briefing materials this week